Abstract Chimeric Antigen Receptor (CAR) T cell therapies–adoptive T cell therapies that
have been genetically engineered for a new antigen-specificity-have displayed significant …

Relapse is a major cause of treatment failure after allogeneic hematopoietic stem cell
transplantation (alloHSCT). Treatment options for relapse have been inadequate, and the …

Background Patients with diffuse large B-cell lymphoma that is refractory to primary and
second-line therapies or that has relapsed after stem-cell transplantation have a poor …

Disease relapse remains a major cause of mortality following allogeneic hematopoietic cell
transplantation (HCT). Over the past decade, our understanding of the biology underlying …

Background Patient outcomes are poor for aggressive B-cell non-Hodgkin's lymphomas not
responding to or progressing within 12 months after first-line therapy. Tisagenlecleucel is an …

Background Despite treatment with novel therapies and allogeneic stem-cell transplant (allo-
SCT) consolidation, outcomes in adult patients with relapsed or refractory B-precursor acute …

Background In the primary analysis of the pivotal JULIET trial of tisagenlecleucel, an
autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, the best overall …

New treatments are needed for B-cell malignancies persisting after allogeneic
hematopoietic stem cell transplantation (alloHSCT). We conducted a clinical trial of …

Chronic active EBV disease (CAEBV) is a lymphoproliferative disorder characterized by
markedly elevated levels of antibody to EBV or EBV DNA in the blood and EBV RNA or …

Although reduced-intensity conditioning (RIC) and non-myeloablative (NMA)-conditioning
regimens have been used for over a decade, their relative efficacy vs myeloablative (MA) …